<ol class="cite-this-references"><li id="reference-A1033">Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [<a href="/articles/A1033" target="_blank">Article</a>] </li><li id="reference-A415">Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [<a href="/articles/A415" target="_blank">Article</a>] </li><li id="reference-L7423">FDA Approved Drug Products: Losartan Oral Tablets [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L7426">FDA Approved Drug Products: Losartan and Hydrochlorothiazide Oral Tablets [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020387s063lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L7441">Cayman Chemicals: Losartan Potassium MSDS [<a href="https://www.caymanchem.com/msdss/10006594m.pdf" target="_blank">Link</a>] </li></ol>